Ironsides Asset Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Ironsides Asset Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-4,500	Closed	-$280K	–	171
2015 Q3	$280K	Hold	4,500	–	–	0.08%	133
2015 Q2	$378K	Hold	4,500	–	–	0.11%	119
2015 Q1	$338K	Buy	+4,500	New	+$314K	0.09%	122

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ironsides Asset Advisors's XBI Position: Q4 2015 in Review

Ironsides Asset Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2015, closing a stake of 4,500 shares — an estimated $280K sold.

Ironsides Asset Advisors first reported a position in XBI in Q1 2015 and held it in 3 quarters. The position peaked at $378K in Q2 2015. 199 funds tracked by Wall St. Rank hold XBI as of Q4 2015.

Ironsides Asset Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2015 after selling out during the quarter.
Ironsides Asset Advisors sold 4,500 State Street SPDR S&P Biotech ETF shares in Q4 2015, an estimated $280K.
Ironsides Asset Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2015 and held it in 3 quarters.
Ironsides Asset Advisors's State Street SPDR S&P Biotech ETF position peaked at $378K in Q2 2015.
199 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2015.

Based on Ironsides Asset Advisors's 13F filing for Q4 2015, filed 9 Feb 2016.